JNCI Journal of the National Cancer Institute · 2023 · 18 citations · 41 references
Life SciencesCancer BiologyOncologyMolecular OncologyProtein BiochemistryProteomicsCancer BiomarkersCancer ProteomicsClinical ProteomicsProteomic BiomarkersProteomic ProfilingTumor MarkersCancer Risk AssessmentCirculating Protein BiomarkersCirculating Tumor Protein BiomarkersCross EffectPlasma Protein BiomarkersPlasma ProteomicsProteomic Tumor MarkersTumor Proteomics
BACKGROUND: The proteome is an important reservoir of potential therapeutic targets for cancer. This study aimed to examine the causal associations between plasma proteins and cancer risk and to identify proteins with cross-cancer effects. METHODS: Genetic instruments for 3991 plasma proteins were extracted from a large-scale proteomic study. Summary-level data of 13 site-specific cancers were derived from publicly available datasets. Proteome-wide Mendelian randomization and colocalization analyses were used to investigate the causal effect of circulating proteins on cancers. Protein-protein interactions and druggability assessment were conducted to prioritize potential therapeutic targets. Finally, systematical Mendelian randomization analysis between healthy lifestyle factors and cancer-related proteins was conducted to identify which proteins could act as interventional targets by lifestyle changes. RESULTS: Genetically determined circulating levels of 58 proteins were statistically significantly associated with 7 site-specific cancers. A total of 39 proteins were prioritized by colocalization, of them, 11 proteins (ADPGK, CD86, CLSTN3, CSF2RA, CXCL10, GZMM, IL6R, NCR3, SIGLEC5, SIGLEC14, and TAPBP) were observed to have cross-cancer effects. Notably, 5 of these identified proteins (CD86, CSF2RA, CXCL10, IL6R, and TAPBP) have been targeted for drug development in cancer therapy; 8 proteins (ADPGK, CD86, CXCL10, GZMM, IL6R, SIGLEC5, SIGLEC14, TAPBP) could be modulated by healthy lifestyles. CONCLUSION: Our study identified 39 circulating protein biomarkers with convincing causal evidence for 7 site-specific cancers, with 11 proteins demonstrating cross-cancer effects, and prioritized the proteins as potential intervention targets by either drugs or lifestyle changes, which provided new insights into the etiology, prevention, and treatment of cancers.
41
DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart, Yannick Djoumbou-Feunang, An Chi Guo et al. · Nucleic Acids Research · 2017 · 8.8K citations · Full text
Damian Szklarczyk, Katerina Nastou, David Lyon et al. · Nucleic Acids Research · 2020 · 8.6K citations · Full text
The MR-Base platform supports systematic causal inference across the human phenome
Gibran Hemani, Jie Zheng, Benjamin Elsworth et al. · eLife · 2018 · 8.4K citations · Full text